Ipsen craters as pricey rare disease drug is put on hold aga...

Allergan gets FDA okay for paediatric Botox use

Ipsen adds Blueprint's FOP rare disease drug to pipeline for...

Ipsen has added to its rare diseases pipeline after striking an agreement with US biotech Blueprint for a  licence to develop and market a drug for the rare disease fibrodysplasia ossifican

Ipsen launches new syringe for rare disease blockbuster

Ipsen will be launching a new pre-filled syringe for its blockbuster rare disease drug Somatuline (lanreotide) in the EU.

Ipsen to buy rare disease firm Clementia for up to $1.31bn

France’s Ipsen has agreed to buy Canadian rare diseases biotech Clementia Pharmaceuticals in a deal worth up to $1.31 billion.